New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Arrowhead Pharmaceuticals, Inc.
ARWR
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

3B

Biotechnology

Next Earning date - 04 Dec 2024

3B

Biotechnology

Next Earning date - 04 Dec 2024

21.10USD
Shape1.22 ( 6.14%)
favorite-chart

Relative Strenght

12
favorite-chart

Volume Buzz

61%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

47%

Quote Panel

Shape
Updated October 17, 2024
1W 14.43 % 1M 1.54 % 3M -23.66 % 1Y -18.81 %

Key Metrics

Shape
  • Market Cap

    2.62B


  • Shares Outstanding

    124.32M


  • Share in Float

    118.50M


  • Dividende

    0


  • Earning Date

    04 Dec 2024


  • Price Target

    21.1


  • Average Volume

    1.04M


  • Beta

    0.955


  • Range

    17.05-39.83


  • Industry

    Biotechnology


  • Website

    https://arrowheadpharma.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

125.78x

P/S Ratio

7.47x

P/B Ratio

1.0

Debt/Equity

-2741.4%

Net Margin

$-4.7

EPS

How ARWR compares to sector?

P/E Ratio

Relative Strength

Shape

ARWR

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$151M

ShapeNaN%

2025-Revenue

$4.07

Shape-195%

2025-EPS

$94M

Shape45%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Goldman Sachs

initialise

Previous: Not converted

2024-06-05

Now: Neutral

SVB Leerink

upgrade

Previous: Market Perform

2023-04-12

Now: Outperform

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-0.81
vs -0.61

Q4.22

arrow
arrow

N/A

-0.39
vs -0.60

Q1.23

arrow
arrow

+10%

0.45
vs 0.41

Q2.23

arrow
arrow

N/A

-0.96
vs -0.68

Q3.23

arrow
arrow

N/A

-1.03
vs -0.81

Q4.23

arrow
arrow

N/A

-1.24
vs -0.39

Q1.24

arrow
arrow

N/A

-1.02
vs 0.45

Q2.24

arrow
arrow

N/A

-1.38
vs -0.96

Q3.24

arrow
arrow

N/A

-0.97
vs -1.03

Q4.24

arrow
arrow

N/A

-1.27
vs -1.24

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

-18%

31.6M  vs 38.3M

Q4.22

arrow
arrow

+128%

62.5M  vs 27.4M

Q1.23

arrow
arrow

-4%

146.3M  vs 151.8M

Q2.23

arrow
arrow

-51%

15.8M  vs 32.4M

Q3.23

arrow
arrow

-49%

16.1M  vs 31.6M

Q4.23

arrow
arrow

-94%

3.6M  vs 62.5M

Q1.24

arrow
arrow

-100%

NA  vs 146.3M

Q2.24

arrow
arrow

-100%

NA  vs 15.8M

Q3.24

arrow
arrow

+242%

55.1M  vs 16.1M

Q4.24

arrow
arrow

+336%

15.5M  vs 3.6M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-81%

-0.81
vs -0.16

Q4.22

arrow
arrow

-11%

-0.11
vs -0.81

Q1.23

arrow
arrow

+11%

0.11
vs -0.11

Q2.23

arrow
arrow

-28%

-0.28
vs 0.11

Q3.23

arrow
arrow

-40%

-0.40
vs -0.28

Q4.23

arrow
arrow

-83%

-0.83
vs -0.40

Q1.24

arrow
arrow

-26%

-0.26
vs -0.83

Q2.24

arrow
arrow

-52%

-0.52
vs -0.26

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

283

283
vs 282

0%

Q4.22

arrow
arrow

292

292
vs 283

3%

Q1.23

arrow
arrow

267

267
vs 292

-9%

Q2.23

arrow
arrow

284

284
vs 267

6%

Q3.23

arrow
arrow

257

257
vs 284

-10%

Q4.23

arrow
arrow

282

282
vs 257

10%

Q1.24

arrow
arrow

285

285
vs 282

1%

Q2.24

arrow
arrow

280

280
vs 285

-2%

Earnings Growth

Latest News